Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on medicines for genetic diseases, and its news flow reflects both commercial activity and clinical development progress. Company updates frequently highlight Attruby (acoramidis), a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Investors following BBIO news see regular disclosures on Attruby’s commercial performance and new clinical and real-world data from the ATTRibute-CM program and its open-label extension, including analyses of variant ATTR-CM populations and specific genetic subgroups. BridgeBio also reports on late-stage pipeline milestones, such as Phase 3 results for BBP-418 in LGMD2I/R9, topline data and regulatory plans for encaleret in autosomal dominant hypocalcemia type 1, and registrational studies of infigratinib in children with skeletal dysplasias.
News items often include participation in major medical and investor conferences, where BridgeBio presents moderated digital posters, scientific analyses, and corporate updates. Additional releases cover financial and corporate developments, including quarterly business updates, equity inducement grants, royalty monetization transactions related to acoramidis, and proposed offerings of convertible senior notes.
This BBIO news page on Stock Titan aggregates these announcements so readers can review clinical data disclosures, commercial updates, financing transactions, and governance developments in one place. For investors and observers tracking genetic disease drug development and ATTR-CM therapies, the news feed provides a concise view of BridgeBio’s reported progress and key events over time.
BridgeBio (Nasdaq: BBIO) presented long-term data showing acoramidis provides sustained benefit through Month 54 in ATTR-CM. Continuous treatment reduced all-cause mortality by 44.7% and cardiovascular mortality by 49.3% (both p<0.0001) versus placebo-to-acoramidis.
Acoramidis mitigated NT-proBNP rise, stabilized KCCQ-OS heart-failure scores, was well tolerated long term, and is approved in the U.S., EU, Japan, Switzerland and the UK.
BridgeBio (Nasdaq: BBIO) submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) on March 30, 2026.
The NDA includes interim Phase 3 FORTIFY data showing statistically significant, clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio anticipates U.S. approval and a launch in late 2026/early 2027, is seeking expedited paths in Europe, and notes prior Orphan Drug, Fast Track, and Rare Pediatric designations.
BridgeBio (NASDAQ: BBIO) will present long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial of acoramidis at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28-30, 2026.
A late-breaking oral presentation on survival and disease stabilization is scheduled for March 30 at 2:33 pm CT, plus three posters on biomarker, health-status and real-world survey findings on March 28 and March 30.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity awards approved March 18, 2026 for 29 new employees totaling 70,916 restricted stock units.
One-fourth of each award vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company Plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, pursuant to Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) presented positive Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showing rapid, consistent efficacy and a favorable safety profile.
Key results: 31-second 100MTT benefit at 12 months, CK reductions with 38.3% normalization, comparable serious adverse event rates, and an intended NDA submission in H1 2026.
BridgeBio (Nasdaq: BBIO) will present additional interim Phase 3 FORTIFY data for BBP-418 in LGMD2I/R9 at the MDA Clinical & Scientific Conference in Orlando, March 8-11, 2026. A late-breaking oral presentation on March 11 will report the interim analysis meeting efficacy endpoints; collaborators will deliver one oral talk and four posters.
BridgeBio (Nasdaq: BBIO) reported $154.2M in Q4 2025 revenue and $502.1M for full-year 2025, driven mainly by Attruby net product sales of $146.0M (Q4) and $362.4M (FY). The company announced three positive Phase 3 readouts and plans multiple NDAs in 1H/2H 2026 with U.S. launches anticipated in late 2026/early 2027. Cash, equivalents, and marketable securities totaled $587.5M at year-end; BridgeBio completed issuance of $632.5M 2033 convertible notes in Jan 2026 to support commercial and pipeline operations.
BridgeBio (Nasdaq: BBIO) announced that management will participate in three March 2026 healthcare investor conferences with scheduled fireside chats in Boston and Miami.
Presentations include TD Cowen on March 2, 2026 at 3:50 pm ET, Leerink Partners on March 10, 2026 at 1:00 pm ET, and Barclays on March 11, 2026 at 12:30 pm ET. Live webcasts and 90-day replays will be available on the company website.
BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved February 12, 2026, awarding 76,701 restricted stock units to 34 new employees.
One-fourth of each employee grant vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Grants were made under the company's Plan and Nasdaq Listing Rule 5635(c)(4).
BridgeBio (Nasdaq: BBIO) will report its fourth quarter and full year 2025 financial results and provide a business update after market close on February 24, 2026. The company will host a conference call and live webcast at 4:30 pm ET the same day. A replay will be available on the investor website for 30 days.